# Masitinib in Refractory Active Rheumatoid Arthritis

> **NCT01410695** · PHASE2,PHASE3 · TERMINATED · sponsor: **AB Science** · enrollment: 324 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** masitinib 3 mg
- **DRUG:** masitinib 6.0 mg
- **DRUG:** methotrexate
- **DRUG:** Placebo (methotrexate)
- **DRUG:** Placebo (masitinib)

## Key facts

- **NCT ID:** NCT01410695
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 324 (ACTUAL)
- **Why stopped:** Sponsor decision based on portfolio prioritization
- **Last updated:** 2018-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410695, "Masitinib in Refractory Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01410695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*